Evidence map›Paper›PMID 25624956›Full record

ArticleThe open AIDS journal2014

Immune Suppression by Myeloid Cells in HIV Infection: New Targets for Immunotherapy.

Vikram Mehraj, Mohammad-Ali Jenabian, Kishanda Vyboh, Jean-Pierre Routy

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The open AIDS journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02691065 (Effect of a Treatment Switch from Protease Inhibitor to Raltegravir-based ART on Myeloid Cell Inflammation in HIV-infected Patients.), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02691065 phase4completednot on this mapstarted 2017, after this paper: background citation

Effect of a Treatment Switch from Protease Inhibitor to Raltegravir-based ART on Myeloid Cell Inflammation in HIV-infected Patients.

TypeinterventionalSponsorMcGill University Health Centre/Research Institute of the McGill University Health CentreRan2017 to 2021Enrolled6ConditionsHIVArmsIntegrase Inhibitor
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Maladaptive trained immunity in viral infections.The Journal of clinical investigation · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Tryptophan Catabolism in Chronic Viral Infections: Handling Uninvited Guests.International journal of tryptophan research : IJTR · 2015
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vikram MehrajChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada ; Research Institute, McGill University Health Centre, Montreal, QC, Canada.
Mohammad-Ali JenabianDépartement des Sciences Biologiques et Centre de recherche BioMed, Université du Québec à Montréal (UQAM), Montreal, QC, Canada.
Kishanda VybohChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada ; Research Institute, McGill University Health Centre, Montreal, QC, Canada.
Jean-Pierre RoutyChronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada ; Research Institute, McGill University Health Centre, Montreal, QC, Canada ; Division of Hematology, McGill University Health Centre, Montreal, QC, Canada.
Université du Québec à Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over thirty years of extensive research has not yet solved the complexity of HIV pathogenesis leading to a continued need for a successful cure. Recent immunotherapy-based approaches are aimed at controlling the infection by reverting immune dysfunction. Comparatively less appreciated than the role of T cells in the context of HIV infection, the myeloid cells including macrophages monocytes, dendritic cells (DCs) and neutrophils contribute significantly to immune dysfunction. Host restriction factors are cellular proteins expressed in these cells which are circumvented by HIV. Guided by the recent literature, the role of myeloid cells in HIV infection will be discussed highlighting potential targets for immunotherapy. HIV infection, which is mainly characterized by CD4 T cell dysfunction, also manifests in a vicious cycle of events comprising of inflammation and immune activation. Targeting the interaction of programmed death-1 (PD-1), an important regulator of T cell function; with PD-L1 expressed mainly on myeloid cells could bring promising results. Macrophage functional polarization from pro-inflammatory M1 to anti-inflammatory M2 and vice versa has significant implications in viral pathogenesis. Neutrophils, recently discovered low density granular cells, myeloid derived suppressor cells (MDSCs) and yolk sac macrophages provide new avenues of research on HIV pathogenesis and persistence. Recent evidence has also shown significant implications of neutrophil extracellular traps (NETs), antimicrobial peptides and opsonizing antibodies. Further studies aimed to understand and modify myeloid cell restriction mechanisms have the potential to contribute in the future development of more effective anti-HIV interventions that may pave the way to viral eradication.

Indexed as

Dendritic cells (DCs)HIVimmunotherapymacrophagesmonocytesmyeloid derived suppressor cellsneutrophils.

Identifiers

PMID25624956
PMCPMC4302459
OpenAlexW2083287680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.